MiNK Therapeutics reports FY2024 net loss of $10.8M, improved from $22.5M in 2023

MiNK Therapeutics, Inc.

Net loss for FY2024 was $10.8M ($2.86/diluted share) vs $22.5M ($6.54/share) in 2023.
Cash and cash equivalents at Dec 31, 2024 were $4.6M, up from $3.4M at year-end 2023.
Cash used in operations for FY2024 was $9.6M, compared to $15.8M in 2023.
Clinical progress: AgenT-797 Phase 2 gastric cancer trial enrolling; ARDS data showed ~80% survival in VV ECMO patients.
Raised $5.8M in private financing in 2024; collaboration with Autonomous Therapeutics for RNA-iNKT therapies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.